Radiation Injuries
📧 Sign up to get email alerts when something new happens for Radiation Injuries.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-07-21EMA Authorised: LysaKare (L-arginine hydrochloride;L-lysine hydrochloride) — Novartis Europharm Limited
The EMA has authorised LysaKare (L-arginine hydrochloride; L-lysine hydrochloride) for use in radiation injuries.
-
EMA approval · 2026-06-12EMA Authorised: LysaKare (L-arginine hydrochloride;L-lysine hydrochloride) — Novartis Europharm Limited
LysaKare (L-arginine hydrochloride; L-lysine hydrochloride) has been authorised in the EU for use in Radiation Injuries.
-
EMA approval · 2026-04-01EMA Authorised: LysaKare (L-arginine hydrochloride;L-lysine hydrochloride) — Advanced Accelerator Applications
EMA authorised LysaKare, a medicine containing L-arginine hydrochloride and L-lysine hydrochloride, for the treatment of radiation injuries.